BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260309
DTEND;VALUE=DATE:20260311
DTSTAMP:20260515T025834
CREATED:20251016T091056Z
LAST-MODIFIED:20251016T091056Z
UID:42214-1773014400-1773187199@www.pharmajournalist.com
SUMMARY:7th Annual AI in Drug Discovery Conference
DESCRIPTION:The 7th Annual AI in Drug Discovery Conference\, hosted by SAE Media Group\, takes place \n9-10 March 2026 at Hilton London Kensington. This event explores how AI\, machine learning\, and automation are transforming drug discovery – from generative design and molecular modelling to clinical trial optimisation. \nAttendees will hear from Big Pharma and Biotech senior leaders including Novartis\, GSK\, AstraZeneca\, Sanofi\, and more\, with sessions covering LLMs\, autonomous agents\, and MLOps. With sponsors like Schrödinger\, the conference delivers cutting-edge insights\, high-level networking\, and practical strategies to accelerate innovation. \nBook now
URL:http://www.pharmajournalist.com/event/7th-annual-ai-in-drug-discovery-conference/
LOCATION:Hilton London Kensington\, 179-199 Holland Park Ave\, London\, W11 4UL\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:alessandra.demaria@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260226
DTEND;VALUE=DATE:20260228
DTSTAMP:20260515T025834
CREATED:20251009T103636Z
LAST-MODIFIED:20251009T103636Z
UID:42156-1772064000-1772236799@www.pharmajournalist.com
SUMMARY:Targeted Therapies Partnering & Licensing Summit Asia
DESCRIPTION:Accelerate Licensing & Co-Development in Asia: Providing Pharma De-Risked Assets to Fuel Pipelines Faster\, & Biotech Access to International Partnerships & Capital \nWith fast\, cost-effective clinical infrastructure\, generous government incentives\, and simplified regulatory pathways\, Asia’s biotech ecosystem has emerged as a global launchpad for innovation. Western pharma and biotech companies are increasingly turning to de-risked assets from Asia to supercharge their clinical pipelines and gain a competitive edge. \nFor NewCo\, private and public biotech or small pharma\, this accessible forum offers: \n\nHigh seniority and quality of attendees across pharma and other biotech\nTargeted focus\, purpose-built format\, and One-on-One Partnering™ portal allowing you to make meaningful connections easier and more efficient\nInformative presentations and discussions nuanced to considerations for deal-making across targeted therapies\n\nVIEW THE FULL EVENT GUIDE \nSecure your place here or get in touch with the team – info@hansonwade.com
URL:http://www.pharmajournalist.com/event/targeted-therapies-partnering-licensing-summit-asia/
LOCATION:The Westin Tokyo\, 1-4-1 Mita Meguro-ku\, Tokyo\, Tokyo 153-8580\, Japan
ORGANIZER;CN="Hanson Wade":MAILTO:General Enquiries: info@hansonwade.com or Partnership Enquiries: sponsor@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260224
DTEND;VALUE=DATE:20260227
DTSTAMP:20260515T025834
CREATED:20251204T131433Z
LAST-MODIFIED:20251204T131433Z
UID:42559-1771891200-1772150399@www.pharmajournalist.com
SUMMARY:LEAP HR: Life Sciences Europe 2026
DESCRIPTION:Now in its 8th year\, LEAP HR: Life Sciences Europe is where the industry’s most ambitious HR leaders come together to find new solutions to their most pressing people challenges that they can immediately deploy to demonstrate meaningful business impact. Uncover the boldest strategies for driving talent agility\, embedding AI and analytics\, and building future-ready workforces – proven to cut costs\, boost engagement\, and accelerate growth. \nThis is the only forum dedicated to the unique and specific HR\, L&D\, and TA opportunities and challenges faced by life science organisations of all sizes across Europe. Join us next February to collaborate with like-minded HR leaders and uncover how to attract\, develop\, and retain top talent in a rapidly changing landscape. \nOver three jam-packed days\, gain actionable takeaways with proven ROI through case studies\, structured networking\, dedicated panels\, roundtable discussions\, and speed learning sessions. Topics range from employment engagement in uncertain marketers to AI-driven HR innovation\, creative compensation design\, and more. \nYou’ll connect with peers who are reimagining HR’s role as driver of strategic value and organizational impact\, sharing real-world case studies\, practical solutions\, with the ROI behind every leap. \nTo learn more and download the agenda\, please click here.
URL:http://www.pharmajournalist.com/event/leap-hr-life-sciences-europe-2026/
LOCATION:Novotel London West\, 1 Shortlands\, Hammersmith\, London\, W6 8DR\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:leaphr@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260224
DTEND;VALUE=DATE:20260227
DTSTAMP:20260515T025834
CREATED:20251204T130129Z
LAST-MODIFIED:20251204T130911Z
UID:42543-1771891200-1772150399@www.pharmajournalist.com
SUMMARY:3rd IMPACCT Real World Evidence Summit Europe
DESCRIPTION:As regulators and payers increasingly elevate the importance of RWE in submission and reimbursement requirements\, the upcoming EHDS regulation marks a landmark move towards data sharing\, and increasingly robust AI transforms big data analysis\, it has never been more critical to harness RWE to uncover unmet needs\, demonstrate treatment value beyond the clinical trial setting\, and influence decision-making across regulators\, payers\, providers\, and patients. \nThe 3rd IMPACCT Real World Evidence Summit Europe is the only industry meeting dedicated to uniting experts in RWE\, Evidence Generation\, and Medical Affairs to consolidate\, innovate and apply RWE across the drug development lifecycle\, from external control arms to reimbursement. \nWith a tight focus on leveraging AI for big data analysis\, accessing standardised and high-quality datasets\, and creating a robust integrated evidence strategy\, join 60+ industry pioneers from AstraZeneca\, Pfizer\, Novartis\, Boehringer Ingelheim and more to collaboratively establish best practice and bridge the evidence gap between clinical research and practice. \nTo learn more and download the agenda\, please click here.
URL:http://www.pharmajournalist.com/event/3rd-impacct-real-world-evidence-summit-europe/
LOCATION:Radisson Blu Hotel\, Rusland 17\, Amsterdam\, 1012 CK\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260224
DTEND;VALUE=DATE:20260227
DTSTAMP:20260515T025834
CREATED:20251121T123049Z
LAST-MODIFIED:20251121T123049Z
UID:42464-1771891200-1772150399@www.pharmajournalist.com
SUMMARY:Measuring Impact in Medical Affairs Summit
DESCRIPTION:The Measuring Impact in Medical Affairs Summit is uniting Medical Affairs leaders from across pharma and biotech to define\, benchmark\, and standardize meaningful KPIs that capture the true value of Medical Affairs activities. \nAs Medical Affairs cements its role as the strategic bridge between R&D and commercialization\, the pressure to quantify and communicate impact has never been greater. In an era of tighter budgets\, digital transformation\, and AI-driven analytics\, teams must move beyond activity tracking to demonstrate measurable outcomes that drive scientific\, stakeholder\, and commercial success. \nThis year\, join 50+ experts from Boehringer Ingelheim\, Abbvie\, Alexion\, Travere\, Regeneron\, and more to explore how leading teams are designing metrics that reflect quality over quantity\, leveraging AI to enhance insight generation\, and co-creating the next generation of KPIs defining Medical Affairs excellence. Don’t miss the only meeting dedicated to transforming Medical Affairs from an activity-based to an impact-driven function. \nFind out more: https://ter.li/ymwe2l
URL:http://www.pharmajournalist.com/event/measuring-impact-in-medical-affairs-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260223
DTEND;VALUE=DATE:20260225
DTSTAMP:20260515T025834
CREATED:20260106T121653Z
LAST-MODIFIED:20260106T121736Z
UID:42640-1771804800-1771977599@www.pharmajournalist.com
SUMMARY:SmartLab Exchange Europe
DESCRIPTION:Across pharma\, biotech\, chemicals\, FMCG\, and beyond\, laboratory leaders are facing the same challenge: how to turn the vision of a smart\, digital lab into reality. From harmonising data and making it AI-ready to unlocking the true value of automation\, the journey from concept to execution is complex – but critical. \nSmartLab Exchange Europe 2026 is where innovation meets implementation. This exclusive\, invitation-only event brings together senior laboratory\, R&D\, and digital transformation leaders to focus on practical strategies that make digitalisation work in practice. Over two days in Amsterdam\, you’ll explore how to overcome data silos\, scale automation\, and drive adoption – from the bench to the boardroom. \nThrough curated roundtables\, one-to-one meetings\, and real-world case studies\, you’ll gain actionable insights on: \n\nHow to efficiently sort your lab data so that it becomes ‘FAIR’\nPractical steps to make sure data is AI-ready\nCase studies from those already implementing AI and Automation to prove the value that can be unlocked\nHow to overcome resistance and drive change across teams and systems\n\nWho Should Attend?\nSenior professionals in R&D\, QA/QC\, IT\, and digital transformation roles from pharma\, biotech\, chemicals\, FMCG\, and food & beverage organisations. \nLearn More:\nView the event guide to explore the full agenda\, speaker lineup\, and venue details to see why the SmartLab Exchange Europe is the must-attend event for laboratory leaders. \nSpaces are strictly limited. Secure your invitation today and join us in Amsterdam for two days of strategic collaboration and innovation.
URL:http://www.pharmajournalist.com/event/smartlab-exchange-europe-2026/
LOCATION:Leonardo Royal Hotel Amsterdam\, Netherlands
ORGANIZER;CN="IQPC Exchange":MAILTO:enquire@iqpc.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260223
DTEND;VALUE=DATE:20260227
DTSTAMP:20260515T025834
CREATED:20251021T104830Z
LAST-MODIFIED:20251021T104830Z
UID:42225-1771804800-1772150399@www.pharmajournalist.com
SUMMARY:16th World ADC London
DESCRIPTION:The Longest Standing & Pre-Eminent European ADC Forum\n16th World ADC London | 800+ Industry Attendees | 240+ Companies | 110+ Global Speakers \nWith traditional ADCs now fulfilling their potential to reshape oncology care\, the bioconjugate community is doubling down on differentiation to ensure the next generation delivers meaningful patient impact. \nReturning as the longest-standing and definitive ADC forum in Europe\, 16th World ADC London 2026 is the must-attend event for anyone working in or looking to learn about bioconjugates. Leverage cutting-edge R&D\, strategic insights\, and unparalleled networking to advance ADC innovation and maximise therapeutic potential. \nAgenda Highlights:\nThe 2026 programme features 5 end-to-end content streams covering discovery\, preclinical translation\, clinical lessons\, process & analytical development\, and manufacturing & supply chain. Sessions are infused with trailblazing approaches to overcome patient resistance and accelerate ADCs into earlier-line oncology treatments. Topics include: \n\nNovel cytotoxic and non-cytotoxic payloads\nDual payload ADCs\nBispecific and biparatopic ADCs\nNon-antibody and fragment conjugates\n\nGlobal Speaker Faculty:\nHear from 110+ experts across Europe\, North America\, and Asia sharing actionable insights to advance your pipeline\, including: \n\nElaine Hurt\, Executive Director & Head\, Tumour Targeted Delivery Bioscience\, Oncology R&D\, AstraZeneca\nGuillaume Bergthold\, Executive Director\, Clinical Development\, Daiichi Sankyo\nAlan Russell\, VP Research & Head\, R&D Technology & Innovation\, Amgen\nAndras Strassz\, Chief Medical Officer\, Heidelberg Pharma\nMarija Vrljic\, VP\, Antibody Technologies\, ALX Oncology (New Company)\nJonathan Davis\, Director\, ADC Discovery\, Helix Biopharma (New Company)\nZhenwei Miao\, Founder & Chairman\, Adcoris Biopharma (New Company)\n\nWho Will Attend:\nJoin 800+ senior ADC decision-makers from biopharma\, clinical research\, service providers\, investors\, and regulators\, uniting to shape the future of ADC development. \nExplore the full agenda for a complete breakdown of all sessions\, speakers\, and networking opportunities.
URL:http://www.pharmajournalist.com/event/16th-world-adc-london/
LOCATION:ExCeL London\, Royal Victoria Dock\, 1 Western Gateway\, London\, E16 1XL\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260203
DTEND;VALUE=DATE:20260206
DTSTAMP:20260515T025834
CREATED:20251111T143537Z
LAST-MODIFIED:20251111T143537Z
UID:42367-1770076800-1770335999@www.pharmajournalist.com
SUMMARY:2nd Proteomics-Based Drug Discovery Summit
DESCRIPTION:With Novartis committing $750M to ProFound Therapeutics to discover new cardiovascular candidates\, and Illumina acquiring SomaLogic for $425 to expand its proteomic capabilities just this year alone\, the increasing recognition of proteomics as a transformative force in drug discovery is unquestionable. \nReturning to Boston for its second year\, the Proteomics-Based Drug Discovery Summit is the premier industry event dedicated to harnessing the full power of proteomics across drug discovery pipelines. Designed for scientific innovators like you\, explore how next-generation proteomic platforms are accelerating understanding of pathology\, unveiling novel drug targets\, and transforming hit-to-lead development. \nWith a special focus on optimizing proteomics instruments to balance throughput and sensitivity\, automating sample processing\, unveiling hidden disease mechanisms with PTM analysis\, and defining gold-standard analysis methodologies; this forum is ideal for proteomics leaders aiming to expand the druggable proteome and achieve therapeutic options for diseases with unmet need. \nAs proteomics continues to evolve\, make headlines\, and revolutionize therapeutic development\, unite with 70+ Directors\, Vice Presidents and Experts in Proteomics\, Chemical Biology\, Mass Spectrometry and Bioinformatics to achieve protein level insights to advance your own discovery pipeline. \nTo know more visit: https://ter.li/t6xjio
URL:http://www.pharmajournalist.com/event/2nd-proteomics-based-drug-discovery-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260203
DTEND;VALUE=DATE:20260206
DTSTAMP:20260515T025834
CREATED:20251111T142214Z
LAST-MODIFIED:20251111T142214Z
UID:42355-1770076800-1770335999@www.pharmajournalist.com
SUMMARY:10th Liquid Biopsy for Precision Oncology Summit
DESCRIPTION:The past decade has transformed liquid biopsy\, which was previously just an exciting concept\, into a routine\, commercially viable technology that is saving patients’ lives and transforming clinical trials. \nUniting the field in San Diego February 3-5\, 2026 for 3 days of data- and strategy-driven presentations and networking sessions\, the 10th Liquid Biopsy for Precision Oncology Summit returns to deliver unparalleled insights\, data\, technology updates\, and strategies spanning the entire drug development pipeline – from preclinical discovery\, through clinical translation\, to regulatory approval\, reimbursement\, and commercial adoption. \nIf you are working in precision oncology\, or need enhanced insights into your patient population\, optimized diagnostic and prognostic tools\, or earlier detection of disease\, this meeting should be considered a staple entry in your conference calendar. Across ctDNA\, MRD\, multi-omic biomarkers\, and novel analytes\, you will see how pharma are strategically integrating liquid biopsies into therapeutic pipelines\, how diagnostic companies are designing more sensitive assays\, and how the field is overcoming barriers to widespread clinical adoption. \n\nSee the full event guide here: https://ter.li/nwkakw\nWith free* tickets available for biopharma\, visit the website to register: https://ter.li/2ewl2u\n\n*Subject to terms and conditions
URL:http://www.pharmajournalist.com/event/10th-liquid-biopsy-for-precision-oncology-summit/
LOCATION:San Diego Marriot La Jolla\, 4240 La Jolla Village Dr\, La Jolla\, CA\, 92037\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260203
DTEND;VALUE=DATE:20260206
DTSTAMP:20260515T025834
CREATED:20250919T104339Z
LAST-MODIFIED:20250919T104709Z
UID:41969-1770076800-1770335999@www.pharmajournalist.com
SUMMARY:14th Alzheimer's & Parkinson's Drug Development Summit
DESCRIPTION:Alzheimer’s and Parkinson’s pipelines are rapidly expanding beyond amyloid and into next-generation mechanisms such as α-synuclein\, neuroinflammation\, and metabolic targets. Against the backdrop of a globally surging patient population\, the urgency for more effective\, disease-modifying interventions has never been greater. \nIn its 14th year\, the Alzheimer’s and Parkinson’s Drug Development Summit is committed to spotlighting the latest trailblazing innovation\, from novel interventions for disease modification\, encompassing protein aggregation\, neuroinflammation\, metabolic pathways\, neurotrophic factors and more to the groundbreaking progress in p-tau217 and fluid-based biomarkers. \nThe 2026 program is built to explore disease progression\, modification and prodromal intervention\, so the next generation of therapeutics can prevent as well provide a meaningful impact to neurodegenerative patients in need. \nWhat can you expect? \n\n2 deep dive workshops into in vivo and in vitro modelling advancements\nSeminar day on fluid-based biomarker innovation\n30+ expert speakers including industry leaders\, academic KOLs and patient voices\nMultiple tracks of content spanning discovery\, preclinical\, clinical and regulatory\n10+ hours dedicated networking time over 3 days\n\nDon’t miss your opportunity to connect with leading drug developers and discover next-generation therapeutics redefining neurodegenerative treatment. \nFind out more here – https://ter.li/ybtrdq
URL:http://www.pharmajournalist.com/event/14th-alzheimers-parkinsons-drug-development-summit/
LOCATION:Hyatt Regency Boston Harbor\, 101 Harborside Drive\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260128
DTEND;VALUE=DATE:20260130
DTSTAMP:20260515T025834
CREATED:20251119T141849Z
LAST-MODIFIED:20251204T124644Z
UID:42408-1769558400-1769731199@www.pharmajournalist.com
SUMMARY:10th Tumor Models Summit San Francisco
DESCRIPTION:Join the West Coast’s premier pharma and biotech gathering\, the 10th Tumor Models Summit San Francisco\, where innovation meets opportunity in tumor modeling. \nAs the FDA phases out animal testing requirements and NIH redirects funding away from animal-only studies\, the oncology landscape is transforming. Exciting modalities like ADCs\, bispecifics\, T-cell engagers demand smarter\, more predictive models. CRISPR and AI are accelerating patient-derived model development at unprecedented speed. \nThis meeting unites industry leaders with cutting-edge vendors to navigate this pivotal shift. Network with pioneers shaping the future of optimizing model selection strategy\, discover breakthrough technologies\, and position your pipeline ahead of the curve. The industry is evolving; the time is now to be part of the conversation. \nDownload the full event guide to find out more: https://ter.li/phkowi
URL:http://www.pharmajournalist.com/event/10th-tumor-models-summit-san-francisco/
LOCATION:Hyatt Centric Fisherman’s Wharf\, 555 North Point St\, San Francisco\, 94133\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260127
DTEND;VALUE=DATE:20260130
DTSTAMP:20260515T025834
CREATED:20251204T125152Z
LAST-MODIFIED:20251204T125420Z
UID:42534-1769472000-1769731199@www.pharmajournalist.com
SUMMARY:6th Age-Related Disease Therapeutics Summit
DESCRIPTION:The 6th Age-Related Disease Therapeutics Summit is the leading global meeting dedicated to advancing therapies that target the biology of aging and age-related diseases. \nOver three days\, the summit brings together senior decision-makers from biopharma\, biotech innovators\, investors\, and academic researchers to accelerate the development and commercialization of next-generation therapeutics. \nAs the aging population grows\, the demand for interventions that extend healthspan and treat chronic conditions is at an all-time high. This meeting provides a unique platform for professionals to explore cutting-edge science\, clinical progress\, and translational strategies shaping this rapidly evolving field. \nFrom senolytics and cellular rejuvenation to mitochondrial health and systemic inflammation\, the summit covers the most promising approaches in age-related disease treatment. \nKey highlights include: \n\nDeep-dive sessions on therapeutic targets\, biomarker validation\, and regulatory pathways.\nInvestment & Funding Insights: Hear from leading investors and strategists on where capital is flowing in longevity and age-related disease innovation.\nNetworking Opportunities: Connect with C-suite executives\, R&D leaders\, and pioneering scientists driving breakthroughs in aging biology.\n\nHere are just some of the ground-breaking companies that will be presenting this year: \nAge 1 | BioAge Labs | Biolexis Therapeutics | Gordian Biotechnology | Insilico Medicine | Juvenescence | Kendall Capital Partners | Novartis | Rubedo Life Sciences | Telocyte \nFind out more\, here: https://ter.li/b3tokv
URL:http://www.pharmajournalist.com/event/6th-age-related-disease-therapeutics-summit-2026/
LOCATION:Hyatt Centric Fisherman’s Wharf\, 555 North Point Street\, San Francsico\, CA\, 94133\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260127
DTEND;VALUE=DATE:20260130
DTSTAMP:20260515T025834
CREATED:20251111T143842Z
LAST-MODIFIED:20251111T143842Z
UID:42373-1769472000-1769731199@www.pharmajournalist.com
SUMMARY:5th mRNA-Based Therapeutics Summit Europe
DESCRIPTION:The 5th mRNA-Based Therapeutics Summit Europe is the leading European industry-focused forum dedicated to accelerating the safe\, scalable\, and clinically impactful development of messenger RNA (mRNA) medicines. Returning for its fifth year in Berlin from 27 – 29 January 2026\, this essential meeting unites 170+ senior leaders across R&D\, CMC (Chemistry\, Manufacturing\, and Controls)\, Regulatory Affairs\, Clinical Development\, and Business Strategy from Europe and around the globe. \nThe summit provides a comprehensive\, end-to-end program\, featuring never-before-seen preclinical and clinical data from industry trailblazers such as Moderna\, AstraZeneca\, and BioNTech. The agenda is meticulously structured to address the field’s most pressing challenges and opportunities: broadening mRNA’s scope beyond infectious disease vaccines into oncology\, rare diseases\, and beyond; overcoming the key bottleneck of targeted and tissue-specific delivery; and resolving complex CMC and stability hurdles for next-generation modalities like self-amplifying RNA (saRNA) and circular RNA (circRNA). \nNew for 2026 is a dedicated Gene Editing Focus Day\, highlighting how mRNA technology enables safer\, transient editing strategies and exploring its translational potential in regenerative indications. Attendees will gain actionable\, exclusive insights on critical topics including advanced LNP and polymeric delivery systems\, manufacturing scale-up\, and the integration of AI into mRNA design. \nAdditionally\, the summit offers high-profile investor sessions\, providing candid perspectives on the clinical milestones\, strategic proof points\, and investment signals necessary to make an mRNA platform fundable in today’s competitive landscape. By fostering collaboration and sharing best practices\, the 5th mRNA-Based Therapeutics Summit Europe is the premier platform to de-risk development pipelines and ensure the next generation of revolutionary mRNA medicines successfully reach patients. \nTo know more visit: https://ter.li/t3lsz2
URL:http://www.pharmajournalist.com/event/5th-mrna-based-therapeutics-summit-europe/
LOCATION:Hotel Palace Berlin\, Germany
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260127
DTEND;VALUE=DATE:20260130
DTSTAMP:20260515T025834
CREATED:20251111T142519Z
LAST-MODIFIED:20251111T142519Z
UID:42360-1769472000-1769731199@www.pharmajournalist.com
SUMMARY:4th Molecular Glue Drug Development Summit
DESCRIPTION:Molecular glues are leading the charge in the race to drug the previously undruggable\, and 2025 has seen continued investment and partnerships driving innovation in this field. Returning as the industry’s only dedicated meeting\, the 4th Molecular Glue Drug Development Summit brings top experts from biopharma and academia together for intimate networking and scientific content sharing. Designed to address the unique challenges of molecular glues\, this meeting will provide actionable strategies to accelerate the development of safer\, more selective candidates toward the clinic. \nAttendees will explore cutting-edge topics including target selection principles\, rational design frameworks\, sensitive assay technologies\, lead optimization\, and AI/ML approaches for rapid and reliable glue discovery. Delve into emerging frontiers in non-degrading molecular glues and approaches outside oncology to unlock new therapeutic modalities\, expand glues to novel indications\, and stay ahead of the curve in the glues space. \nIf you’re looking to lead the way in the molecular glue space\, connect with the brightest minds\, and gain practical insights to drive programs forward – this is your chance to solve the field’s unique challenges and shape the next wave of innovative therapies. \nExplore the 3 day event guide: https://ter.li/rhdyz0
URL:http://www.pharmajournalist.com/event/4th-molecular-glue-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260127
DTEND;VALUE=DATE:20260130
DTSTAMP:20260515T025834
CREATED:20251104T084713Z
LAST-MODIFIED:20251104T100827Z
UID:42309-1769472000-1769731199@www.pharmajournalist.com
SUMMARY:7th RNAi-Based Therapeutics Summit
DESCRIPTION:2025 is proving to be a landmark year for RNAi. From Alnylam’s first approval in hemophilia to Novartis’ $1.2 billion acquisition of Avidity Biosciences and GSK diving into COPD with an $85 million siRNA licensing deal\, the headlines haven’t stopped. RNAi is officially outgrowing its liver roots and entering a new era of therapeutic expansion. \nWith so much momentum shaping the RNAi landscape\, there’s never been a more pivotal time for the community to come together. The 7th RNAi-Based Therapeutics Summit (January 27-29\, 2026 | Boston\, MA) is the industry-dedicated forum uniting the entire RNAi ecosystem from discovery and complex chemistry to clinical development and CMC. \nLearn more in the official event program here: https://ter.li/8c4zw3 \nThrough 30+ expert-led sessions\, explore how pioneers are moving beyond the liver to unlock new disease frontiers: \nExpanding Horizons to Systemic & Extrahepatic Diseases: \nReprogram metabolic health with dual-targeting siRNA for obesity and leverage multi-gene silencing miRNA to overcome chemo-resistance\, moving beyond appetite suppression and single-target inhibition for durable\, tissue-specific efficacy. \nBreaking Barriers in Brain & CNS Delivery: \nOvercome the blood-brain barrier with Trojan Horse formulations and intrathecal delivery to achieve significant protein knockdown in neurodegenerative diseases\, paving a clear path toward clinical development for severe neurological disorders. \nExamining Innovative Delivery Strategies for Enhanced Targeting: \nUtilize novel ligand platforms\, antibody conjugates\, and DNA origami nanostructures to achieve precise delivery to muscle\, kidney\, and adipose tissue\, optimizing cellular uptake and endosomal escape to avoid the limitations of conventional LNPs. \nEngineering Specificity & Safety Through Chemical Biology: \nApply advanced phosphorothioate patterns and 2′-modifications to transcend GalNAc\, actively directing biodistribution and improving therapeutic indices to build safer\, more precise RNAi drugs. \nOptimizing CMC & Formulation for Commercial Readiness:  \nAddress the unique synthesis\, characterization\, and manufacturing challenges of complex conjugates and novel chemistries to ensure quality\, stability\, and scalability for clinical and commercial supply. \nJoin discovery to clinical development teams from the top pharma and biotechs to de-risk your path to the clinic and accelerate your extrahepatic pipeline. \nWant to find more about registration options? Follow this link to go to the registration platform on our website: https://ter.li/n7bmw8
URL:http://www.pharmajournalist.com/event/7th-rnai-based-therapeutics-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260127
DTEND;VALUE=DATE:20260130
DTSTAMP:20260515T025834
CREATED:20251007T061903Z
LAST-MODIFIED:20251009T110319Z
UID:42127-1769472000-1769731199@www.pharmajournalist.com
SUMMARY:4th Ophthalmic Drug Delivery Summit
DESCRIPTION:With global cases of AMD\, DME\, and glaucoma rapidly increasing\, ophthalmic drug R&D is accelerating to meet urgent unmet needs. However\, poor treatment adherence\, invasive procedures\, and adverse side effects continue to limit therapeutic success\, highlighting the critical need for optimized delivery approaches. \nRecent developments\, including Genentech’s Susvimo label expansion\, advances in sustained-release and suprachoroidal delivery systems\, and Regeneron’s acquisition of Oxular\, demonstrate a growing industry focus on improving durability and reducing invasiveness. \nThat’s why 80+ industry leaders will gather at the 4th Ophthalmic Drug Delivery Summit this January to explore long-acting intravitreal and subretinal innovations\, emerging suprachoroidal techniques\, novel formulation strategies\, drug-device integration\, and evolving regulatory expectations. \nJoin experts across preclinical and clinical R&D\, formulation\, pharmacology\, devices\, and combination products for three days of focused discussions driving the future of safe\, effective\, and durable ophthalmic therapies. \nDownload the full event guide to find out all the topics to be discussed and the full expert speaker faculty: https://ter.li/vz7y60
URL:http://www.pharmajournalist.com/event/4th-ophthalmic-drug-delivery-summit/
LOCATION:Hilton San Francisco Financial District\, 750 Kearny St\, San Francisco\, CA\, 94108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260127
DTEND;VALUE=DATE:20260130
DTSTAMP:20260515T025834
CREATED:20251003T101634Z
LAST-MODIFIED:20251003T101634Z
UID:42113-1769472000-1769731199@www.pharmajournalist.com
SUMMARY:Non-Opioid Pain Therapeutics Summit
DESCRIPTION:The race to deliver safe\, effective non-opioid pain therapeutics has never been more urgent – or more achievable. After decades of setbacks\, the field is achieving long-awaited progress with recent regulatory approvals from Tonix and Vertex\, strategic acquisitions from Eli Lilly\, and late-stage successes validating the commercial potential of novel mechanisms. \nHowever\, the clinical pathway for pain remains one of the most challenging in drug development\, requiring smarter trial design\, validated endpoints\, patient stratification strategies\, and strong regulatory engagement. \nThe Inaugural Non-Opioid Pain Therapeutics Summit is the only meeting dedicated to overcoming the unique scientific and clinical barriers in pain drug development. Discussions will focus on optimizing trial design in chronic pain\, advancing mechanism-specific biomarkers\, addressing placebo response and patient stratification\, and aligning with regulators on validated endpoints. \nWith case studies spanning NaV inhibitors\, novel receptor targets\, and first-in-class modalities\, the summit provides the scientific depth and clinical perspective required to move non-opioid pain candidates successfully through the pipeline. \nAttendees will be learning from companies with approvals such as Tonix\, exploring late-stage strategies from innovators like Latigo and Algiax\, and uncovering discovery breakthroughs from Nocion and Axonis. Join 70+ discovery\, preclinical\, translational and clinical industry-based experts driving the future of non-opioid pain therapies across diverse pain indications. \nTo know more visit: https://ter.li/h7pe87
URL:http://www.pharmajournalist.com/event/non-opioid-pain-therapeutics-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251209
DTEND;VALUE=DATE:20251211
DTSTAMP:20260515T025834
CREATED:20251009T103909Z
LAST-MODIFIED:20251009T103909Z
UID:42161-1765238400-1765411199@www.pharmajournalist.com
SUMMARY:7th CNS Drug Delivery Summit
DESCRIPTION:Unlocking Safer\, More Efficient Delivery to Targeted Brain Regions by Advancing Direct\, & Systemic Delivery to the CNS Via TfR1 & Beyond \nDespite milestones such as Roche’s Trontinemab Brainshuttle™ achieving robust amyloid clearance\, challenges remain in reaching targeted brain regions\, improving predictive modelling\, ensuring efficacy and penetrance\, and developing safer\, targeted delivery approaches. \nJoin 100+ industry experts spanning neuroscientists\, chemists\, device engineers\, conjugation scientists\, DMPK experts\, delivery specialists\, and more at the 7th CNS Drug Delivery Summit to collaborate\, network\, and learn cutting-edge strategies that are tackling the unique challenges in gaining access to the brain. \nVIEW THE FULL EVENT GUIDE \nSecure your place here or get in touch with the team – info@hansonwade.com
URL:http://www.pharmajournalist.com/event/7th-cns-drug-delivery-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:General Enquiries: info@hansonwade.com or Partnership Enquiries: sponsor@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251209
DTEND;VALUE=DATE:20251212
DTSTAMP:20260515T025834
CREATED:20250919T115220Z
LAST-MODIFIED:20250919T115220Z
UID:42013-1765238400-1765497599@www.pharmajournalist.com
SUMMARY:2nd ADC Pharmacokinetics & Clinical Pharmacology Summit
DESCRIPTION:With the launch of the FDA’s Project Optimus\, and the evolving clinical pharmacology guidelines for ADCs\, the need to identify an optimal clinical dose that balances safety with efficacy has never been more evident. \nBringing together a focused audience of clinical pharmacology\, PK\, pharmacometrics\, modelling\, and bioanalysis specialists\, the 2nd ADC Pharmacokinetics & Clinical Pharmacology Summit returns to Boston December 9-11\, 2025. \n\nInvestigate non-traditional payloads and bispecific ADCs to understand how unique PK properties influence clinical outcomes with AstraZeneca & Tavotek\nExplore dose optimization and adjustment through modelling and simulation\, with Astellas\nJoin Abbvie & Daiichi Sankyo to use bioanalytical methods to assess structural integrity and DAR for deeper insights into drug clearance\nApply QSP platforms with Novartis to rigorously evaluate the predictive value of computational modelling\nLeverage AI and enhance ADME parameter understanding with Sutro Biopharma & University at Buffalo\n\nSee the event guide: https://ter.li/vrojuh
URL:http://www.pharmajournalist.com/event/2nd-adc-pharmacokinetics-clinical-pharmacology-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251208
DTEND;VALUE=DATE:20251211
DTSTAMP:20260515T025834
CREATED:20251003T095343Z
LAST-MODIFIED:20251003T095343Z
UID:42107-1765152000-1765411199@www.pharmajournalist.com
SUMMARY:LEAP TD: Life Sciences
DESCRIPTION:As biopharma organizations decrease their budgets and move away from a recruitment-centric approach\, the need to develop existing talent to fill key technical skills gaps has never been more mission critical. \nThis December in Boston\, LEAP TD: Life Sciences will bring together senior talent development leaders from across biopharma to explore how learning and development can directly support scientific progress and organizational resilience. \nJoin 60+ senior L&D\, HR\, and training leaders from top biotech and pharma organizations to transform your L&D strategy to develop and retain a highly skilled\, agile scientific while building a resilient leadership pipeline to accelerate innovative research and development. This is your opportunity to rethink how learning\, leadership\, and a renewed focus on strategic workforce planning can drive measurable business impact\, commercial\, and scientific success. \nHow will attending help you? \n\nAccelerate workforce readinessby designing learning interventions that evolve with AI\, automation\, and cutting-edge scientific advancements\nBridge critical talent gapsthrough career pathways that upskill teams in biomanufacturing\, regulatory science\, and data fluency\nEmpower future-ready leaderswith the capabilities to navigate complexity\, drive innovation\, and lead transformational change\n\nAttending companies include Bristol Myers Squibb\, Vertex Pharma\, Biogen\, Labcorp\, Kyowa Kirin\, Arcus Biosciences\, Takeda\, and many other leading biotech and pharma organizations. \nThrough focused case studies and peer-led discussions\, attendees will uncover how leading teams are embedding development into the daily realities of regulated environments\, enabling leadership at every level\, and designing learning experiences that reflect the complexity of life sciences work. Whether you’re building scalable mentorship programs\, rethinking onboarding for scientific roles\, or aligning development with compliance and innovation goals\, this is your opportunity to connect with peers facing similar challenges and leave with strategies that drive measurable impact. \nThis is not another L&D expo. It’s a strategic\, high-level forum where talent development\, training\, and L&D leaders working in life sciences come together to discuss their talent development challenges and uncover new strategies in a collaborative environment. \nTo learn more about the event and find out whether this is the event that you need to take your biopharma workforce to the next level\, view the event brochure here: https://ter.li/jyi8dj.
URL:http://www.pharmajournalist.com/event/leap-td-life-sciences/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:leaphr@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251203
DTEND;VALUE=DATE:20251205
DTSTAMP:20260515T025834
CREATED:20250827T112407Z
LAST-MODIFIED:20250827T112407Z
UID:41782-1764720000-1764892799@www.pharmajournalist.com
SUMMARY:14th Tumour Models Summit London
DESCRIPTION:With the European oncology market increasingly focused on emerging modalities\, highlighted by AbbVie’s recent licensing agreement with Ichnos Glenmark Innovation for their trispecific antibody\, Boehringer Ingelheim’s partnership with Tempus to advance their cancer pipeline and the FDA’s new roadmap and the EMA encouraging drug developers to use non-animal tests in submissions\, there has never been a more important year to stay up to date with the latest innovations in tumour modelling. \nAs the longest-standing forum from the world-renowned Tumour Models event series\, the 14th Tumour Models Summit London returns to unite 130+ tumour modelling experts from pharma\, biotech\, and model providers from across the UK and Western Europe to soundboard recent model selection strategies with the goal of bridging the translational gap to the clinic. \nDownload the event guide for full details: https://ter.li/hsztzb
URL:http://www.pharmajournalist.com/event/14th-tumour-models-summit-london/
LOCATION:Park Plaza Victoria London\, 239 Vauxhall Bridge Road Pimlico\, London\, SW1V 1EQ\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251202
DTEND;VALUE=DATE:20251205
DTSTAMP:20260515T025834
CREATED:20250805T115734Z
LAST-MODIFIED:20250805T120701Z
UID:41643-1764633600-1764892799@www.pharmajournalist.com
SUMMARY:3rd Cell Therapy for Autoimmune Disease Summit
DESCRIPTION:Ever since the field-defining studies in Nature Medicine and the New England Journal demonstrated that cell therapies could hold lasting potential in lupus and beyond\, the field has grown from strength to strength. With a surge of billion-dollar investments\, the release of new groundbreaking data\, and recent real-world clinical progression\, the autoimmune cell therapy field is poised for clinical and commercial success. \nThe 3rd Cell Therapy for Autoimmune Disease Summit (December 2-4 | Philadelphia\, PA) returns at a pivotal time\, providing first-hand insights and case studies needed to keep your team ahead in this fast-evolving space. Reconnect with 130+ scientific pioneers\, with expertise spanning CAR-T\, Treg\, in vivo and NK cell therapies\, as they unveil the latest clinical data and cutting-edge innovations redefining the chronic care of autoimmune indications. \nAccess Your Brand-New 2025 Agenda Copy! \nLearn directly from industry titans including Cabaletta Bio\, Kyverna Therapeutics\, Umoja Biopharma\, Cartesian Therapeutics\, Century Therapeutics\, Artiva Biotherapeutics and Novartis\, to benchmark your current strategies and gain a competitive edge amongst your peers to accelerate your lead candidate from preclinical innovation to clinical success. \nWhether you are preparing for your first clinical trials\, or making the transition into later phases\, our carefully curated two-tracked agenda (now expanded to the Workshop Day!) has content tailored for you. \n\nPreclinical & Translational: Address challenges in antigen selection\, delve into autologous and allogeneic translational strategies\, and discuss alternatives to B-cell depletion\, to bring the next wave of therapies to the clinic.\nClinical: Unpack trial design\, evaluate long-term clinical outcomes\, share regulatory strategies\, and learn how to operationalize studies for broader patient access.\n\nWith cell therapy companies increasingly targeting autoimmune diseases\, and autoimmune companies continuing to embrace cellular approaches\, ensure you join the industry’s definitive meeting committed to transforming the promise of cell therapies in autoimmunity into reality. \nEvent Guide | Register | Learn More
URL:http://www.pharmajournalist.com/event/3rd-cell-therapy-for-autoimmune-disease-summit/
LOCATION:Sheraton Philadelphia Downtown\, 201 N 17th Street\, Philadelphia\, PA\, 19103\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251202
DTEND;VALUE=DATE:20251205
DTSTAMP:20260515T025834
CREATED:20250919T105408Z
LAST-MODIFIED:20250919T105408Z
UID:41976-1764633600-1764892799@www.pharmajournalist.com
SUMMARY:6th Gene Therapy for Ophthalmic Disorders Summit
DESCRIPTION:The 6th Gene Therapy for Ophthalmic Disorders Summit returns to Raleigh\, North Carolina\, as the leading industry forum dedicated to accelerating the development of gene therapies for both rare and common eye diseases. With irreversible vision loss progressing rapidly in many conditions\, gene therapy continues to emerge as a critical one-time intervention that can preserve and restore sight for patients in need. \nMomentum in 2025 is stronger than ever. Kriya Therapeutics is advancing its preclinical pipeline\, Opus Genetics and SpliceBio are progressing into early trials\, while Ocugen\, 4D Molecular Therapeutics\, and AbbVie are racing toward BLA approval. Against this backdrop of progress\, challenges around endpoint selection\, funding strategies\, and safe delivery methods remain at the forefront. The summit provides a unique platform to tackle these issues head-on and drive forward meaningful breakthroughs. \nAttendees will gain access to exclusive data and insights\, including preclinical updates from Opus Genetics\, Coave Therapeutics\, and Axovia Therapeutics\, alongside pivotal 2025 clinical progress shared by Ocugen\, Adverum Biotechnologies\, and Beacon Therapeutics. A major highlight is the Interview the Investor session with James Kasuboski\, Partner & Head of Research at Luma Group\, where attendees will hear directly from investors on the criteria shaping ophthalmic gene therapy funding and strategies for building sustainable development approaches. \nAdditional sessions will spotlight patient-led regulatory engagement\, comparative analyses of delivery approaches\, and strategies for optimizing trial design and patient retention. With a carefully balanced agenda – equally split between preclinical and clinical content – this meeting provides a comprehensive view of the ophthalmic gene therapy pipeline. \nFeaturing 18+ senior expert speakers\, 3+ hours of clinical data\, 2+ hours of preclinical research\, and 6+ hours of networking opportunities\, the summit unites biopharma leaders\, investors\, and innovators to accelerate progress from IND through to late-stage clinical development. \nJoin us in Raleigh to connect with decision-makers across the ophthalmic gene therapy value chain\, uncover the next wave of breakthroughs beyond Luxturna\, and ensure your therapy reaches patients faster. \n View the full event program on our website here: https://ter.li/0duhtz
URL:http://www.pharmajournalist.com/event/6th-gene-therapy-for-ophthalmic-disorders-summit/
LOCATION:DoubleTree by Hilton Raleigh Midtown\, 2805 Highwoods Blvd\, Raleigh\, NC\, 27604\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251202
DTEND;VALUE=DATE:20251205
DTSTAMP:20260515T025834
CREATED:20250905T114029Z
LAST-MODIFIED:20250905T114054Z
UID:41892-1764633600-1764892799@www.pharmajournalist.com
SUMMARY:5th Applied Biocatalysis & Enzyme Engineering Summit
DESCRIPTION:Navigate New FDA Leadership\, Harness AI-Powered Submissions & Align Technical Innovation with the Latest Nonclinical\, Clinical & CMC Guidance to Overcome Regulatory Challenges and Accelerate Your Path to Clinic & Market \nWith major FDA changes already reshaping the regulatory landscape – and global agencies ramping up scrutiny – 2025 is a pivotal year for cell and gene therapy regulatory professionals. With CBER leadership changes\, new FDA draft guidance on post-approval CMC\, and potency assays facing heightened scrutiny\, the environment is rapidly evolving. Global efforts to align expectations are also gaining momentum\, with ANVISA and Health Canada joining harmonization initiatives\, and ICH Q12 implementation for CGTs underway. \nThe 2nd Cell & Gene Therapy Regulatory Affairs Summit is the only industry-led event focused exclusively on CGT regulatory strategy. Join 80+ experts this December in Washington\, D.C. for real-world case studies\, insights from regulators\, and deep dives into IND-to-BLA planning\, global alignment\, and emerging modalities. \nIf you’re navigating nonclinical\, clinical\, or CMC submissions\, this is your essential forum to stay ahead of shifting expectations and accelerate CGT approvals in 2025 and beyond. \nLearn more: https://ter.li/c211fx
URL:http://www.pharmajournalist.com/event/5th-applied-biocatalysis-enzyme-engineering-summit/
LOCATION:Washington Marriott Capitol Hill\, 175 L St NE\, Washington\, WA\, 20002\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251202
DTEND;VALUE=DATE:20251204
DTSTAMP:20260515T025834
CREATED:20250905T112712Z
LAST-MODIFIED:20250905T112817Z
UID:41881-1764633600-1764806399@www.pharmajournalist.com
SUMMARY:Designing the AI-Enabled Biopharma Workforce Summit
DESCRIPTION:The World’s Only Industry-Specific Forum on AI-Oriented Skills-Centric Workforce Transformation in Life Sciences\nMost roles in biopharma organizations will undergo an AI-driven transformation in the coming years. But exactly how that transformation manifests itself\, in what jobs\, with what skills\, and across what proportion of our workforces is not yet fully clear. \nWhat is clear\, though\, is that the future depends on what we do now. The most forward-thinking companies already know that innovation doesn’t just happen at the bench\, it also takes place company-wide in working out what needs to be done\, how\, and by whom. \nThey are building future workforce capability faster by reassessing the needs of each department and fundamentally rethinking what work is best done by people versus what can be automated with technology. For the first time\, this forum will shine a light on how this is done. \nTaking part will help you approach organizational design with a new perspective which is skills centric\, rather than job centric and allow you to walk away with a new skills taxonomy that will help you deliver more productivity and more innovation from fewer people in less time. \nDownload the Agenda
URL:http://www.pharmajournalist.com/event/designing-the-ai-enabled-biopharma-workforce-summit/
LOCATION:W Boston\, 100 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="LEAP HR":MAILTO:leaphr@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251202
DTEND;VALUE=DATE:20251205
DTSTAMP:20260515T025834
CREATED:20250829T120338Z
LAST-MODIFIED:20250829T120338Z
UID:41820-1764633600-1764892799@www.pharmajournalist.com
SUMMARY:2nd Cell & Gene Therapy Regulatory Affairs Summit
DESCRIPTION:With major FDA changes already reshaping the regulatory landscape – and global agencies ramping up scrutiny – 2025 is a pivotal year for cell and gene therapy regulatory professionals. With CBER leadership changes\, new FDA draft guidance on post-approval CMC\, and potency assays facing heightened scrutiny\, the environment is rapidly evolving. Global efforts to align expectations are also gaining momentum\, with ANVISA and Health Canada joining harmonization initiatives\, and ICH Q12 implementation for CGTs underway. \nThe 2nd Cell & Gene Therapy Regulatory Affairs Summit is the only industry-led event focused exclusively on CGT regulatory strategy. Join 80+ experts this December in Washington\, D.C. for real-world case studies\, insights from regulators\, and deep dives into IND-to-BLA planning\, global alignment\, and emerging modalities. \nIf you’re navigating nonclinical\, clinical\, or CMC submissions\, this is your essential forum to stay ahead of shifting expectations and accelerate CGT approvals in 2025 and beyond. \nFind out more: https://ter.li/c211fx
URL:http://www.pharmajournalist.com/event/2nd-cell-gene-therapy-regulatory-affairs-summit/
LOCATION:Washington Marriott Capitol Hill\, 175 L St NE\, Washington\, WA\, 20002\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251202
DTEND;VALUE=DATE:20251205
DTSTAMP:20260515T025834
CREATED:20250820T122909Z
LAST-MODIFIED:20250820T122909Z
UID:41738-1764633600-1764892799@www.pharmajournalist.com
SUMMARY:2nd Innovation in Obesity Therapeutics Summit
DESCRIPTION:The 2nd Innovation in Obesity Therapeutics Summit will return to San Diego this December. Hear from the titans of the pharmaceutical industry\, including Novo Nordisk\, Eli Lilly and Boehringer Ingelheim\, who will share their groundbreaking research and strategies. The pressure is on to develop best-in-class treatments that transform patient lives. \nDon’t miss this pivotal opportunity to network with 60+ experts in the field of obesity\, forge crucial collaborations\, and be part of the solution. \nFind out more here: https://ter.li/vnapww
URL:http://www.pharmajournalist.com/event/2nd-innovation-in-obesity-therapeutics-summit/
LOCATION:DoubleTree by Hilton Hotel San Diego – Mission Valley\, 7450 Hazard Center Dr\, San Diego\, CA\, 92108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251202
DTEND;VALUE=DATE:20251205
DTSTAMP:20260515T025834
CREATED:20250812T104500Z
LAST-MODIFIED:20250812T104500Z
UID:41714-1764633600-1764892799@www.pharmajournalist.com
SUMMARY:8th RNA-Targeted Drug Discovery & Development Summit
DESCRIPTION:RNA-targeting small molecules are rapidly emerging as a powerful therapeutic reality. From modulating splicing to directly binding RNAs\, these molecules offer a revolutionary approach to treating previously undruggable diseases across neurodegenerative\, cancer and rare disorders. In 2025 alone\, the field has seen major collaborations\, including Wayfinder Biosciences with Daiichi Sankyo\, Ono Pharmaceutical with Reborna Biosciences\, and xFOREST with Astellas Pharma—signaling growing momentum and industry confidence. \nNow in its 8th year\, the RNA-Targeted Drug Discovery & Development Summit returns as the only dedicated industry forum addressing the unique challenges of RNA-targeted drug development across splice modulators\, covalent drugs\, proximity inducers and direct RNA binders.\nJoin 25+ world-class speakers from leaders like PTC Therapeutics\, ReviR Therapeutics\, Remix Therapeutics\, Rgenta Therapeutics\, Arrakis Therapeutics and more this December to gain the connections\, tools and scientific firepower needed to bring your RNA-targeted therapeutics to clinic and beyond. \nStep into the future of RNA-targeted drugs at the 8th RNA-Targeted Drug Discovery & Development Summit. With 75% new speakers from 2024 and 50% of the speakers sharing new data\, this summit is set to offer the latest data and fresh insights on small molecules targeting RNA. \nThis year\, join 80+ experts in RNA biology\, drug discovery\, medicinal chemistry\, and structural biology to gain the latest data on visualizing dynamic RNA structures\, identifying functional binders\, improving selectivity\, enhancing delivery stability and achieving oral bioavailability. \nWhether you’re focused on RNA splice modulators\, covalent binders\, proximity inducing drugs\, or direct RNA binders this event will give you the tools and insights to fast track the discovery of functional binders and accelerate your pipeline of RNA-targeted small molecules to the clinic. \nConnect with your global community at the world’s only meeting for RNA-targeted drug experts. \nTo know more visit: https://ter.li/rcvdor
URL:http://www.pharmajournalist.com/event/8th-rna-targeted-drug-discovery-development-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251201
DTEND;VALUE=DATE:20251204
DTSTAMP:20260515T025834
CREATED:20250820T123645Z
LAST-MODIFIED:20250820T123645Z
UID:41743-1764547200-1764806399@www.pharmajournalist.com
SUMMARY:7th Cell Therapy Analytical Development Summit
DESCRIPTION:Recognized as the industry’s leading forum for cell therapy analytical\, quality control\, assay\, and CMC professionals\, the 7th Cell Therapy Analytical Development Summit\, returns to Boston to provide the expertise needed to prepare your teams for clinical and commercial readiness. Hear directly 80+ experts from Takeda\, Arsenal Bio\, Bayer\, Genentech\, Adicet Bio\, Quell Therapeutics\, and the National Institute of Health\, as they share proven strategies\, innovative technologies and best-in-class approaches to enhance your product safety and quality\, ahead of regulatory approval. \nNow combined with the previously separate\, Cell Therapy Potency Assay Summit\, this meeting provides you with an even more comprehensive agenda\, covering the full landscape of analytical development\, across early- and late-stage assay development tracks. Join us this December to fast-track the next era of safe\, potent and robust cell therapies to market! \nFor more information\, please visit https://ter.li/9uagdj
URL:http://www.pharmajournalist.com/event/7th-cell-therapy-analytical-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251201
DTEND;VALUE=DATE:20251204
DTSTAMP:20260515T025834
CREATED:20250812T105107Z
LAST-MODIFIED:20250812T105107Z
UID:41720-1764547200-1764806399@www.pharmajournalist.com
SUMMARY:9th Complement-Based Drug Development Summit
DESCRIPTION:Diving Into the Complement Cascade to Explore Intervention Points\, Harnessing Biomarker Strategies to Identify Optimal Patient Populations\, & Exploring the Therapeutic Opportunity from Rare Disease to Inflammation to Autoimmune Disease. \nSo far\, 2025 has brought significant excitement and progress to the complement-based therapeutic landscape. Leading biopharma companies like Novartis\, Annexon Biosciences and Omeros\, are making significant clinical progress in PNH\, AMD\, IgAN and C3G\, whilst key academics such as Michael Holers\, Michael Brenner\, and Brahm Segal continue to make discoveries in complement imaging\, novel pathways\, and new therapeutics areas such as oncology and transplantation. \nThe Complement-Based Drug Development Summit returns for its 9th year to unite the leading experts in complement biology and therapeutic development\, from innovative biotech to impactful large pharma and academic experts. This meeting will harness the energy and dedication deepening the current understanding of the complement system to advance drug development in rare disease and beyond with patients at the forefront. \nJoin us at the 2025 meeting to gain insights from 20+ expert speakers covering the end-to-end complement-based drug development\, from basic biology to diagnostics and clinical development. \nParticipate in three dedicated workshops for active discussion on key topics including the intracellular complement system\, bispecific complement mediators\, and innovative delivery of complement-based therapeutics to ensure delivery to the correct targets. \nThis comprehensive program spans a broad spectrum of renal\, ophthalmic\, neurological\, and haematological indications\, mirroring the shift in focus of the complement field from rare orphan indications to larger patient populations. \nJoin 80+ industry experts this December and access exclusive insights into therapeutic development across the complement field and bring actionable learnings and competitive intelligence back to your team.
URL:http://www.pharmajournalist.com/event/9th-complement-based-drug-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR